IRIS Accounts Production v26.2.0.496 05223275 director 1.9.25 31.5.26 31.5.26 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh052232752025-08-31052232752026-05-31052232752025-09-012026-05-31052232752024-08-31052232752024-09-012025-08-31052232752025-08-3105223275ns15:EnglandWales2025-09-012026-05-3105223275ns14:PoundSterling2025-09-012026-05-3105223275ns10:Director12025-09-012026-05-3105223275ns10:PrivateLimitedCompanyLtd2025-09-012026-05-3105223275ns10:SmallEntities2025-09-012026-05-3105223275ns10:AuditExempt-NoAccountantsReport2025-09-012026-05-3105223275ns10:SmallCompaniesRegimeForDirectorsReport2025-09-012026-05-3105223275ns10:SmallCompaniesRegimeForAccounts2025-09-012026-05-3105223275ns10:FullAccounts2025-09-012026-05-310522327512025-09-012026-05-3105223275ns10:OrdinaryShareClass12025-09-012026-05-3105223275ns10:RegisteredOffice2025-09-012026-05-3105223275ns5:CurrentFinancialInstruments2026-05-3105223275ns5:CurrentFinancialInstruments2025-08-3105223275ns5:ShareCapital2026-05-3105223275ns5:ShareCapital2025-08-3105223275ns5:RetainedEarningsAccumulatedLosses2026-05-3105223275ns5:RetainedEarningsAccumulatedLosses2025-08-3105223275ns5:NetGoodwill2025-09-012026-05-3105223275ns5:IntangibleAssetsOtherThanGoodwill2025-09-012026-05-3105223275ns5:FurnitureFittings2025-09-012026-05-3105223275ns5:MotorVehicles2025-09-012026-05-3105223275ns5:NetGoodwill2025-08-3105223275ns5:NetGoodwill2026-05-3105223275ns5:NetGoodwill2025-08-3105223275ns5:FurnitureFittings2025-08-3105223275ns5:MotorVehicles2025-08-3105223275ns5:ComputerEquipment2025-08-3105223275ns5:ComputerEquipment2025-09-012026-05-3105223275ns5:FurnitureFittings2026-05-3105223275ns5:MotorVehicles2026-05-3105223275ns5:ComputerEquipment2026-05-3105223275ns5:FurnitureFittings2025-08-3105223275ns5:MotorVehicles2025-08-3105223275ns5:ComputerEquipment2025-08-3105223275ns5:WithinOneYearns5:CurrentFinancialInstruments2026-05-3105223275ns5:WithinOneYearns5:CurrentFinancialInstruments2025-08-3105223275ns5:AcceleratedTaxDepreciationDeferredTax2026-05-3105223275ns5:AcceleratedTaxDepreciationDeferredTax2025-08-3105223275ns5:DeferredTaxation2025-08-3105223275ns5:DeferredTaxation2025-09-012026-05-3105223275ns5:DeferredTaxation2026-05-3105223275ns10:OrdinaryShareClass12026-05-3105223275ns10:Director112025-08-3105223275ns10:Director112024-08-3105223275ns10:Director112025-09-012026-05-3105223275ns10:Director112024-09-012025-08-3105223275ns10:Director112026-05-3105223275ns10:Director112025-08-31
REGISTERED NUMBER: 05223275 (England and Wales)















Shil Pharmacy Limited

Unaudited Financial Statements

for the Period 1 September 2025 to 31 May 2026






Shil Pharmacy Limited (Registered number: 05223275)






Contents of the Financial Statements
for the Period 1 September 2025 to 31 May 2026




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


Shil Pharmacy Limited

Company Information
for the Period 1 September 2025 to 31 May 2026







Director: Mrs S Desai





Registered office: 5th Floor Hodge House
114-116 St Mary Street
Cardiff
CF10 1DY





Registered number: 05223275 (England and Wales)





Accountants: Menzies LLP, Statutory Auditors
5th Floor Hodge House
114-116 St Mary Street
Cardiff
CF10 1DY

Shil Pharmacy Limited (Registered number: 05223275)

Statement of Financial Position
31 May 2026

2026 2025
Notes £    £   
Fixed assets
Intangible assets 4 - -
Property, plant and equipment 5 9,430 50,436
9,430 50,436

Current assets
Inventories 30,204 30,204
Debtors 6 316,707 399,246
Cash at bank and in hand 33,956 184,535
380,867 613,985
Creditors
Amounts falling due within one year 7 (387,575 ) (407,889 )
Net current (liabilities)/assets (6,708 ) 206,096
Total assets less current liabilities 2,722 256,532

Provisions for liabilities 8 (2,358 ) (12,610 )
Net assets 364 243,922

Capital and reserves
Called up share capital 9 1 1
Retained earnings 363 243,921
Shareholders' funds 364 243,922

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 May 2026.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 May 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 July 2026 and were signed by:





Mrs S Desai - Director


Shil Pharmacy Limited (Registered number: 05223275)

Notes to the Financial Statements
for the Period 1 September 2025 to 31 May 2026

1. Statutory information

Shil Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2004, is being amortised evenly over its estimated useful life of twenty years.

The director believes that the estimate useful life of the goodwill at the date of transition to FRS 102 (section 1A) was reliable.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Fixtures and fittings - 15% on cost
Motor vehicles - 25% on reducing balance

Inventories
Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Financial instruments are classified and accounted for according to the substance of the contractual arrangements as either financial assets, financial liabilities or equity instruments, and are held at amortised cost. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all its liabilities.

Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


Shil Pharmacy Limited (Registered number: 05223275)

Notes to the Financial Statements - continued
for the Period 1 September 2025 to 31 May 2026

2. Accounting policies - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. Employees and directors

The average number of employees during the period was 9 (2025 - 13 ) .

4. Intangible fixed assets
Goodwill
£   
Cost
At 1 September 2025
and 31 May 2026 50,000
Amortisation
At 1 September 2025
and 31 May 2026 50,000
Net book value
At 31 May 2026 -
At 31 August 2025 -

5. Property, plant and equipment
Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
Cost
At 1 September 2025 67,416 69,385 1,195 137,996
Disposals - (69,385 ) - (69,385 )
At 31 May 2026 67,416 - 1,195 68,611
Depreciation
At 1 September 2025 56,890 30,356 314 87,560
Charge for period 1,843 - 134 1,977
Eliminated on disposal - (30,356 ) - (30,356 )
At 31 May 2026 58,733 - 448 59,181
Net book value
At 31 May 2026 8,683 - 747 9,430
At 31 August 2025 10,526 39,029 881 50,436

Shil Pharmacy Limited (Registered number: 05223275)

Notes to the Financial Statements - continued
for the Period 1 September 2025 to 31 May 2026

6. Debtors: amounts falling due within one year
2026 2025
£    £   
Trade debtors 269,989 264,121
Other debtors 4,901 4,901
Directors' current accounts 21,000 112,446
Tax 1,880 -
VAT 18,937 16,266
Prepayments - 1,512
316,707 399,246

7. Creditors: amounts falling due within one year
2026 2025
£    £   
Bank loans and overdrafts - 367
Trade creditors 239,218 227,809
Tax - 31,802
Social security and other taxes 2,344 2,074
Net wages 13,572 12,076
Pension 592 631
Accruals and deferred income 131,849 133,130
387,575 407,889

8. Provisions for liabilities
2026 2025
£    £   
Deferred tax
Accelerated capital allowances 2,358 12,610

Deferred
tax
£   
Balance at 1 September 2025 12,610
Credit to Income Statement during period (10,252 )
Balance at 31 May 2026 2,358

9. Called up share capital

Allotted, issued and fully paid:
Number: Class: Nominal 2026 2025
value: £    £   
1 Ordinary £1 1 1

10. Transactions with directors

The following advances and credits to a director subsisted during the period ended 31 May 2026 and the year ended 31 August 2025:

2026 2025
£    £   
Mrs S Desai
Balance outstanding at start of period 112,446 39,312
Amounts advanced 111,355 113,134
Amounts repaid (202,801 ) (40,000 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of period 21,000 112,446

Shil Pharmacy Limited (Registered number: 05223275)

Notes to the Financial Statements - continued
for the Period 1 September 2025 to 31 May 2026

10. Transactions with directors - continued

During the period Shil Pharmacy Limited paid rents of £13,500 (2025, year £18,000) to Mrs S Desai, director and sole shareholder of the company.